Autres langues Verrica Pharmaceuticals Inc.

Actions

VRCA

US92511W1080

Marché Fermé - Nasdaq Autres places de cotation 22:30:01 03/05/2024			Varia. 5j.	Varia. 1 janv.
7,26 ^USD	+7,40%		+5,68%	-0,82%

26/03	L'Ycanth de Verrica Pharmaceuticals obtient le statut de nouvelle entité chimique et une inscription dans l'Orange Book	MT
26/03	Verrica Pharmaceuticals annonce que YCANTH ? reçoit le statut de nouvelle entité chimique et la liste Orange Book de la FDA	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Verrica Pharmaceuticals Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference	02/04
Verrica Pharmaceuticals Announces that YCANTH Receives New Chemical Entity Status and Orange Book Listing from the FDA	27/03
Verrica Pharmaceuticals' Ycanth Gets New Chemical Entity Status, Orange Book Listing	26/03
Verrica Pharmaceuticals Announces that YCANTH™ Receives New Chemical Entity Status and Orange Book Listing from the FDA	26/03
Verrica Pharmaceuticals Announces that YCANTH? Receives New Chemical Entity Status and Orange Book Listing from the FDA	26/03
VERRICA PHARMACEUTICALS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Verrica Pharmaceuticals Inc. - VRCA	09/03
Verrica Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/02
Verrica Pharmaceuticals Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	29/02
Earnings Flash (VRCA) VERRICA PHARMACEUTICALS Reports Q4 Revenue $2M, vs. Street Est of $950,000	29/02
Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results	29/02
Verrica Pharmaceuticals Announces Participation in the TD Cowen 44th Annual Healthcare Conference	27/02
Verrica Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full-Year 2023 Financial Results on February 29, 2024	22/02
Verrica Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full-Year 2023 Financial Results on February 29, 2024	22/02
VERRICA PHARMACEUTICALS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Verrica Pharmaceuticals Inc. - VRCA	14/02
Verrica Pharmaceuticals Sues Dormer Labs for Promoting Unapproved Cantharidin Drugs in US	05/02
Verrica Pharmaceuticals Files Lawsuit Against Canadian Drug Manufacturer for False Advertising and Unfair Competition	05/02
Verrica Pharmaceuticals Files Lawsuit Against Canadian Drug Manufacturer for False Advertising and Unfair Competition	05/02
Verrica Pharmaceuticals Receives Permanent J-Code for YCANTH from Centers for Medicare and Medicaid Services	30/01
Verrica Pharmaceuticals Receives Permanent J-Code (J7354) for YCANTH™ from Centers for Medicare and Medicaid Services	29/01
Verrica Pharmaceuticals Receives Permanent J-Code for YCANTH from Centers for Medicare and Medicaid Services	29/01

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Verrica Pharmaceuticals Inc.

Actions

VRCA

US92511W1080

Autres langues

Filtres